Who is sponsoring NCT03057275?

NCT03057275 is sponsored by GE Healthcare.

What drugs are being tested in NCT03057275?

Interventions in NCT03057275: Abdominal fetal/maternal monitoring.

What condition does NCT03057275 study?

NCT03057275 studies Premature Labor.

Is NCT03057275 still recruiting?

NCT03057275 is currently completed. Last updated 9 February 2021.

Last reviewed 2021-02-09 · How we verify

NCT03057275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance of the Monica Novii Wireless Patch System in Pre-term Labor

Completed Last updated 9 February 2021

What this trial tests

trial testing Abdominal fetal/maternal monitoring in Premature Labor in 47 participants. Completed in 20 September 2019.

Timeline

20 April 2017

Primary endpoint
20 September 2019

20 September 2019

Quick facts

Lead sponsor	GE Healthcare
Status	Completed
Study type	OBSERVATIONAL
Enrollment	47
Start date	20 April 2017
Primary completion	20 September 2019
Estimated completion	20 September 2019
Sites	1 location across United States

Drugs / interventions tested

Abdominal fetal/maternal monitoring

Conditions studied

Premature Labor — all drugs for Premature Labor →

Sponsor

GE Healthcare — full company profile →

Who can join

18 and older, female only, with Premature Labor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the equivalence of the Monica Novii™ Patch System in patients admitted for threatened pre-term labor and for pre-term labor \& delivery from 32 +0 weeks gestation by determining the equivalence of the Novii™ Patch System in monitoring Fetal Heart Rate (FHR), Maternal Heart Rate (MHR) and Uterine Contractions (UC) to Doppler FHR, tocodynamometer (TOCO) UC and photo plethysmograph MHR FDA approved predicates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Performance of a Maternal Abdominal Surface Electrode System for Fetal Heart Rate and Uterine Contraction Monitoring from 34 to 37 Weeks.
Gonzalez M, Hill M, Cohen WR. · · 2024 · cited 1× · PMID 34666382 · DOI 10.1055/a-1673-1765

Verify or expand the search:

Other GE Healthcare trials

Trials by the same sponsor.

NCT07472491 — A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients · Phase 2, PHASE3 · recruiting
NCT07394140 — NMT EasyFit Sensor and Cable · NA · not yet recruiting
NCT07024472 — NIBP Cuff Comparison Study · completed
NCT06835647 — Maternal Fetal Device Performance Twins · NA · recruiting
NCT06639828 — Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03057275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GE Healthcare
Last refreshed: 9 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03057275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing